Year None2024202320222021202020192018201720162015 Sep 11 Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial Sep 9 Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer Sep 9 Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO Aug 26 Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma Aug 26 Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases Aug 20 Regeneron Provides Update on Biologics License Application for Linvoseltamab Aug 7 Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast Aug 1 Regeneron Reports Second Quarter 2024 Financial and Operating Results Jul 31 Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation Jul 3 Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD First page « Previous page ‹ Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Next page › Last page »